Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study.
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 Australian Biotech
Latest Video
New Stories
-
Moderna announces positive Phase 3 result for influenza vaccine
July 1, 2025 - - Latest News -
Research lagging for sarcoma, despite accounting for one third of adolescent cancer deaths
July 1, 2025 - - Latest News -
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 - - Latest News -
The real question is why expectations were so high in the first place
July 1, 2025 - - Latest News -
National Pharmacies appoints experienced industry leader as new CEO
July 1, 2025 - - Latest News -
Tetratherix lists on the ASX following successful IPO
June 30, 2025 - - Australian Biotech -
LTR Pharma achieves key FDA milestone through extractables study
June 30, 2025 - - Australian Biotech